Notice :
Impact of Recent Change Health Care National Outage. Learn More
Notice :
Impact of Recent Change Health Care National Outage. Learn More

Clinical Trial

Trial Protocol ID USOR 23059_CO44657

Trial Description

A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY

View on ClinicalTrials.gov

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com or call us at 877-664-7724

Investigator

  • Carol Tweed, MD

Disease Types

Sponsor

  • F. Hoffmann-La Roche Ltd

ClinicalTrials.gov NCT ID

  • NCT06065748